Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes

Gelijkaardige items

• Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control
  door: Keche, Yogendra
  Gepubliceerd in: (2010)
• Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes
  door: Fala, Loretta
  Gepubliceerd in: (2015)
• Bedaquiline: First FDA-approved tuberculosis drug in 40 years
  door: Mahajan, Rajiv
  Gepubliceerd in: (2013)
• Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
  door: Gaziano, J. Michael, et al.
  Gepubliceerd in: (2012)
• Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
  Gepubliceerd in: (2015)